Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.

scientific article

Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2013PLoSO...874253X
P356DOI10.1371/JOURNAL.PONE.0074253
P932PMC publication ID3753304
P698PubMed publication ID23991216
P5875ResearchGate publication ID256292109

P50authorJie NiQ38523771
Weiwei XiaoQ64927805
P2093author name stringYong Li
John H Kearsley
Lei Chang
Qihan Dong
Peter H Graham
Carl A Power
Jingli Hao
P2860cites workHistone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairQ26863429
Pathways governing G1/S transition and their response to DNA damageQ28202348
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosisQ28277806
Anticancer activities of histone deacetylase inhibitorsQ29616624
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancerQ33256354
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progressionQ33482138
Sensing and repairing DNA double-strand breaksQ34642563
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoproteinQ34742793
Role of cell cycle in mediating sensitivity to radiotherapyQ35826593
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.Q35864090
Postradiation sensitization of the histone deacetylase inhibitor valproic acidQ36085669
DNA-damage repair; the good, the bad, and the uglyQ36487307
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effectsQ36617012
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsQ36645808
Histone deacetylase inhibitors: signalling towards p21cip1/waf1.Q36782509
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosisQ36849135
Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zeroQ37086523
P53, cyclin-dependent kinase and abnormal amplification of centrosomesQ37109906
Enhancing the apoptotic and therapeutic effects of HDAC inhibitorsQ37440094
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsQ37515346
Developing histone deacetylase inhibitors as anti-cancer therapeuticsQ37856325
Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapyQ37998519
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancersQ38095611
Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancerQ39313134
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cellsQ39580891
Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancerQ39632081
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progressionQ39663662
Attenuated DNA damage repair by trichostatin A through BRCA1 suppressionQ40088892
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX fociQ40240295
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigenQ40545805
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.Q43136243
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.Q46905304
How low is the α/β ratio for prostate cancer?Q47426446
Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpointsQ73681450
Histone deacetylase inhibitorsQ80489191
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P4510describes a project that usesImageQuantQ112270642
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectadaptive radiation therapyQ180507
prostate cancerQ181257
P304page(s)e74253
P577publication date2013-08-26
P1433published inPLOS OneQ564954
P1476titleCombination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells
P478volume8

Reverse relations

cites work (P2860)
Q38911199Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers
Q89078193CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer
Q26771165Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization
Q52590685Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Q53749396Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
Q28071912Epigenetic modulators as therapeutic targets in prostate cancer
Q53575196HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Q35006481Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells
Q38844402Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells
Q35691776Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
Q38951260PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
Q37687556Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.
Q46038047Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
Q38848047Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells
Q50926267Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
Q36810416The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.

Search more.